CXCR4 and rheumatoid arthritis: Considering the prevalence of type I IFNs in RA and their functional activity, the concurrent suppression of IFNs and anti-inflammatory effects of CXCR4 present significant clinical advantages (Rönnblom and Eloranta, 2013).